干旱区生态环境知识资源中心(Arid): Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial

Arid

DOI	10.4088/JCP.21m14130
	Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial
	Berger, Maximus; Li, Emily; Rice, Simon; Davey, Christopher G.; Ratheesh, Aswin; Adams, Sophie; Jackson, Henry; Hetrick, Sarah; Parker, Alexandra; Spelman, Tim; Kevin, Richard; McGregor, Iain S.; McGorry, Patrick; Amminger, G. Paul
通讯作者	Berger, M
来源期刊	JOURNAL OF CLINICAL PSYCHIATRY
ISSN	0160-6689
EISSN	1555-2101
出版年	2022
卷号	83 期号:5
英文摘要	Background: Treatment resistance is a significant problem among young people experiencing moderate-to-severe anxiety, affecting nearly half of all patients. This study investigated the safety and efficacy of cannabidiol (CBD), a non-intoxicating component of Cannabis sativa, for anxiety disorders in young people who previously failed to respond to standard treatment. Methods: In this open-label trial, 31 young people aged 12-25 years with a DSM-5 anxiety disorder and no clinical improvement despite treatment with cognitive-behavioral therapy and/or antidepressant medication were enrolled between May 16, 2018, and June 28, 2019. All participants received add-on CBD for 12 weeks on a fixed-flexible schedule titrated up to 800 mg/d. The primary outcome was improvement in anxiety severity, measured with the Overall Anxiety Severity and Impairment Scale (OASIS), at week 12. Secondary outcomes included comorbid depressive symptoms, Clinical Global Impressions scale (CGI) score, and social and occupational functioning. Results: Mean (SD) OASIS scores decreased from 10.8 (3.8) at baseline to 6.3 (4.5) at week 12, corresponding to a -42.6% reduction (P <.0001). Depressive symptoms (P <.0001), CGI-Severity scale scores (P =.0008), and functioning (P =.04) improved significantly. Adverse events were reported in 25 (80.6%) of 31 participants and included fatigue, low mood, and hot flushes or cold chills. There were no serious and/or unexpected adverse events. Conclusions: These findings suggest that CBD can reduce anxiety severity and has an adequate safety profile in young people with treatment-resistant anxiety disorders. Randomized controlled trials are needed to confirm the efficacy and longer-term safety of this compound.
类型	Article
语种	英语
开放获取类型	Green Submitted
收录类别	SCI-E ; SSCI
WOS记录号	WOS:000898541600005
WOS关键词	PSYCHOMETRIC EVALUATION ; IMPAIRMENT ; SEVERITY ; ANTIDEPRESSANTS ; RELEVANT ; PATTERNS ; UPDATE
WOS类目	Psychology, Clinical ; Psychiatry
WOS研究方向	Psychology ; Psychiatry
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/393388
推荐引用方式 GB/T 7714	Berger, Maximus,Li, Emily,Rice, Simon,et al. Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial[J],2022,83(5).
APA	Berger, Maximus.,Li, Emily.,Rice, Simon.,Davey, Christopher G..,Ratheesh, Aswin.,...&Amminger, G. Paul.(2022).Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial.JOURNAL OF CLINICAL PSYCHIATRY,83(5).
MLA	Berger, Maximus,et al."Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial".JOURNAL OF CLINICAL PSYCHIATRY 83.5(2022).